Ponce Aix S.; Talbot D.; Govindan R.; Dols M.C.; Postmus P.E.; Lewanski C.; Bennouna J.; Fischer J.R.; Juan-Vidal O.; Stewart D.J.; Ardizzoni A.; Bhore R.; Wolfsteiner M.; Reck M.; Ong T.J.; Morgensztern D., Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer, «FUTURE ONCOLOGY», 2020, 16, pp. 749 - 762 [articolo]
Cuicchi D.; Di Fabio F.; Guido A.; Llimpe F.L.R.; Morganti A.G.; Ardizzoni A.; Coscia M.; Poggioli G., Randomized Pilot Trial of Percutaneous Posterior Tibial Nerve Stimulation Versus Medical Therapy for the Treatment of Low Anterior Resection Syndrome: One-Year Follow-up, «DISEASES OF THE COLON & RECTUM», 2020, 63, pp. 1602 - 1609 [articolo]
Ricci C.; Capizzi E.; Giunchi F.; Casolari L.; Gelsomino F.; Rihawi K.; Natali F.; Livi V.; Trisolini R.; Fiorentino M.; Ardizzoni A., Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study, «THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY», 2020, 12, Article number: 1758835920954802, pp. 1 - 8 [articolo]Open Access
Di Nunno V.; Santoni M.; Mollica V.; Conti A.; Montironi R.; Battelli N.; Ardizzoni A.; Massari F., Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients, «CLINICAL DRUG INVESTIGATION», 2020, 40, pp. 211 - 226 [articolo]
Gatti M.; Raschi E.; Poluzzi E.; Martignani C.; Salvagni S.; Ardizzoni A.; Diemberger I., The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia, «CURRENT HEART FAILURE REPORTS», 2020, 17, pp. 365 - 383 [articolo]Open Access
Di Federico A.; Filippini D.M.; Dall'Olio F.G.; Conci N.; Minari R.; Tiseo M.; Ardizzoni A., The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma—letter, «CLINICAL CANCER RESEARCH», 2020, 26, pp. 518 - 519 [articolo]
Lamberti G.; Sisi M.; Andrini E.; Palladini A.; Giunchi F.; Lollini P.-L.; Ardizzoni A.; Gelsomino F., The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players?, «CANCERS», 2020, 12, Article number: 3129, pp. 1 - 21 [articolo]Open Access
Rizzo A.; Mollica V.; Ricci A.D.; Maggio I.; Massucci M.; Rojas Limpe F.L.; Fabio F.D.; Ardizzoni A., Third-and later-line treatment in advanced or metastatic gastric cancer: A systematic review and meta-analysis, «FUTURE ONCOLOGY», 2020, 16, pp. 4409 - 4418 [articolo]
Livi, Vanina; Ardizzoni, Andrea; Cancellieri, Alessandra; Natali, Filippo; Ferrari, Marco; Paioli, Daniela; De Biase, Dario; Capizzi, Elisa; Tallini, Giovanni; Fiorentino, Michelangelo; Trisolini, Rocco, Adequacy of endosonography-derived samples from peribronchial or periesophageal intrapulmonary lesions for the molecular profiling of lung cancer, «THE CLINICAL RESPIRATORY JOURNAL», 2019, 13, pp. 590 - 597 [articolo]
Rihawi K ; Giannarelli D ; Galetta D ; Delmonte A ; Giavarra M ; Turci D ; Garassino M ; Tiseo M ; Barbieri ; Panni S ; Ardizzoni A;, BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience, «JOURNAL OF THORACIC ONCOLOGY», 2019, 14, pp. 57 - 59 [articolo]
Iacovelli, Roberto; Ciccarese, Chiara; Fornarini, Giuseppe; Massari, Francesco; Bimbatti, Davide; Mosillo, Claudia; Rebuzzi, Sara Elena; Di Nunno, Vincenzo; Grassi, Massimiliano; Fantinel, Emanuela; Ardizzoni, Andrea; Tortora, Giampaolo, Cabozantinib-related cardiotoxicity: a prospective analysis in a "real world" cohort of metastatic renal cell carcinoma patients, «BRITISH JOURNAL OF CLINICAL PHARMACOLOGY», 2019, 85, pp. 1283 - 1289 [articolo]
Nuvola G.; Dall'Olio F.G.; Melotti B.; Sperandi F.; Ardizzoni A., Cardiac Toxicity From Afatinib in EGFR-Mutated NSCLC: A Rare But Possible Side Effect, «JOURNAL OF THORACIC ONCOLOGY», 2019, 14, pp. e145 - e146 [articolo]
Capizzi E.; Dall'Olio F.G.; Gruppioni E.; Sperandi F.; Altimari A.; Giunchi F.; Fiorentino M.; Ardizzoni A., Clinical significance of ROS1 5’ deletions in non-small cell lung cancer, «LUNG CANCER», 2019, 135, pp. 88 - 91 [articolo]
Francesco Gelsomino,Giancarlo Facchini, Maria Aurelia Barbera,
Giuseppe Lamberti, Stefano Brocchi, Giuseppe Rossi,
Andrea Ardizzoni, Complete Recalcification Following Arterial Embolization of Massive Osteolytic Bone Metastasis From NSCLC, «JOURNAL OF THORACIC ONCOLOGY», 2019, 14, pp. 141 - 143 [articolo]
Cho B.C.; Obermannova R.; Bearz A.; McKeage M.; Kim D.-W.; Batra U.; Borra G.; Orlov S.; Kim S.-W.; Geater S.L.; Postmus P.E.; Laurie S.A.; Park K.; Yang C.-T.; Ardizzoni A.; Bettini A.C.; de Castro G.; Kiertsman F.; Chen Z.; Lau Y.Y.; Viraswami-Appanna K.; Passos V.Q.; Dziadziuszko R., Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)–Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study, «JOURNAL OF THORACIC ONCOLOGY», 2019, 14, pp. 1255 - 1265 [articolo]
